BCL-2 family proteins have proven to be outstanding targets for cancer therapy, but their importance in controlling normal cell survival often leads to dose-limiting on-target toxicity of BCL-2 inhibitors that induce neutropenia or diarrhea, or BCL-XL inhibitors that result in thrombocytopenia. This evidence concerns the gene BCL2L1 and cancer.